In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, finds itself at a critical juncture as it navigates a complex landscape of opportunities and challenges. The company's recent performance and ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

USA-based healthcare giant Johnson & Johnson has announced the publication of key Phase III data for nipocalimab in The ...

Johnson & Johnson announced The Lancet Neurology has published results from the pivotal Phase 3 study of nipocalimab, an investigational ...

PUCHHEIM, GERMANY - Newsaktuell - 23 January 2025 - ELATEC, a leading global provider of user authentication and ...

In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic response at one year. The FDA has approved Eli Lilly’s Omvoh ...

For example, the FREESIA-1 study is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of nipocalimab for preventing fetal and neonatal ...